Cancer Immunotherapy Markets

Cancer Immunotherapy Markets

Report Overview:

The technologies and opportunities are explored. Over one hundred companies are profiled. Our research makes you the expert.

A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. This is a complex area but our readable reports help you understand it, both the technology and the opportunity.

The technology is moving faster than the market. Already worth billions the global market is poised for dramatic growth. Is the cure in sight? The impact on the health care industry is enormous. The report forecasts the market size out to 2023.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

CAR – T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

1. Introduction and Market Definition
1.1 What is Cancer Immunotherapy?
1.2 Immunotherapy – the looming cure
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Pharmceutical Spending - Perspective
1.5.1 U.S. Expenditures for Pharmaceuticals
2. Immunotherapy – Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system Surface barriers Inflammation Complement system Cellular barriers Natural killer cells
2.0.2 Adaptive immune system Lymphocytes Killer T cells Helper T cells Gamma delta T cells B lymphocytes and antibodies
2.0.3 Tumor immunology – the immune surveillance system
2.1 Immuno Oncology Technologies
2.1.1 Monoclonal Antibodies Outlook for Monoclonal Antibodies Companies with Monoclonal Antibodies in their Pipeline
2.1.2 Cancer vaccines Outlook for Cancer Vaccines Companies with Cancer Vaccines in their Pipeline
2.1.3 Cytokines Outlook for Cytokines Companies with Cytokines in their Pipeline
2.1.4 Cell Based Therapies Outlook for Cell Based Therapies Companies with Cell Based Therapies in their Pipeline
2.1.5 Inhibitors/Agonists Outlook for Inhibitors/Agonists Companies with Inhibitors/Agonists in their Pipeline
2.1.6 Antibody Drug Conjugates Outlook for Antibody Drug Conjugates Companies with Antibody Drug Conjugates in their Pipeline
2.1.7 Others Outlook for Other Therapeutics Companies with Viral Therapeutics in their Pipeline Companies with Other Therapeutics in their Pipeline
3. Industry Overview
3.1 Market Players – Roles & Impacts
3.1.1 Drug manufacturers - Larger/pharmaceutical
3.1.2 Drug manufacturers - Generic
3.1.3 Contract Research and Manufacturing
3.1.4 In Vitro Diagnostics Industry
3.1.5 Drug Marketing Companies
3.1.6 Biotechnology Companies
3.1.7 Regulatory Bodies
4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Fast tracking
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Cost of Treatment
4.2.2 Clinical Trials Role
4.2.3 Combinations
4.2.4 Protocols
4.3 Therapeutic Technology Development
4.3.1 Combinations - Issues and Complexity
4.3.2 Preference for a drug
4.3.3 Problems of Immunity Engineering
4.3.4 The Role of Cost
4.3.5 The Disruption Dynamic
4.3.6 CAR-T Cell Therapy
4.3.7 The Next Five Years
5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
Gritstone to Move Slate Immunotherapy into Clinical Trial
Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for
Immunotherapy Biomarker Discovery in Clinical Trial Participants
Spectrum Announces a Novel Immuno-Oncology Platform including Two Early Stage Assets
FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC
Keytruda Better Than Chemotherapy
Cancer ‘vaccine’ eliminates tumors in mice
Iovance Rides The T-Cell Wave
Overcoming the Current Limitations of Cancer Immunotherapy
Startup focused on cell therapy gets acquired
Positive results in pre-clinical trials for Imugene’s cancer vaccine
Celsion Corporation OPTIMA Study Continues
Regeneron and bluebird bio to Collaborate on Cancer Immunotherapy
Sangamo bulks up in cell therapy with TxCell acquisition
BI dives deeper into cancer immunotherapy with new acquisition
Innovest Global Acquires Stake in StemVax Therapeutics
Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial
FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo
FDA Grants Fast Track Designation to Galinpepimut-S for Treating Multiple Myeloma
BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors
FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal
Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for
Colorectal Cancer
FDA Expedites Tecentriq-Avastin Combo for Most Common Liver Cancer
Immunotherapy Use Can Double Survival Rate of Melanoma Patients with Brain Metastasis
FDA Grants Priority Review to Keytruda-Chemo Combo for Metastatic NSCLC
FDA Approves Phase 2 Trial Testing AIVITA’s Vaccine for Aggressive Brain Cancer
Immunotherapy Candidate M7824 Effective in Advanced Lung Cancer Patients
Apogenix Prepares Submission for Conditional Marketing Authorization in Europe
Immunotherapy Leads to Complete Response in Advanced Breast Cancer Patient
Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows
CBT Pharmaceuticals and CrystalGenomics Announce Partnership
New cancer vaccine against melanoma has 100% success rate
6. Profiles of Key Immunotherapy Companies
10X Genomics
A. Menarini
Adaptimmune Therapeutics PLC
ADC Therapeutics
Aduro Biotech Inc.
Agenus Inc.
AIVITA Biomedical
Aleta Biotherapeutics
Antigen Express Inc
Apeiron Biologics
Apogenix GmbH
Aptose Biosciences
Arcus Biosciences Inc.
Astrazeneca PLC
Atara Biotherapeutics
Atlas Venture
Aurora Biopharma
Autolus Therapeutics plc
Beigene Ltd.
Bellicum Pharmaceuticals
Biovest International Inc
Bluebird bio
BriaCell Therapeutics
Bristol-Myers Squibb
CARsgen Therapeutics
CBT Pharmaceuticals
Celldex Therapeutics
Cellectis S A
Cellular Biomedicine
Celsion Corporation
Chugai Pharmaceutical Co.
Cytomx Therapeutics Inc.
Cytovac A/S
Daiichi Sankyo
Dynavax Technolgy
Eli Lilly and Co.
EMD Serono Inc
Fate Therapeutics Inc.
Five Prime Therapeutics Inc.
Galectin Therapeutics
Genentech Inc
Genmab AS
Gilead Sciences Inc.
Gliknik Inc
GlobeImmune Inc
Gritstone Oncology, Inc
Heat Biologics Inc
Heidelberg Pharma GmbH
Idera Pharmaceuticals, Inc
Immatics Biotechnologies GmbH
Immune Design
Incyte Corporation
Inmune Bio Inc.
Innate Pharma
Iovance Biotherapeutics Inc.
iOx Therapeutics
iTeos Therapeutics
Janssen Global Services (J&J)
Jounce Therapeutics
Juno Therapeutics
Kite Pharma Inc
KSQ Therapeutics
Life Science Pharmaceuticals
MabVax Therapeutics Holdings Inc
Macrogenics Inc.
MedImmune LLC
Merck & Co., Inc
Mirati Therapeutics
Moderna Therapeutics
Morphosys AG
Morphotek Inc
Myriad RBM
Mustang Bio
Nanjing Legend Biotech
NBE Therapeutics
Nekonal Oncology
Nektar Therapeutics
Neon Therapeutics
NewLink Genetics Corp
Noile-Immune Biotech
Northwest Biotherapeutics Inc
Novartis A G
Novelogics Biotechnology, Inc.
Novo Nordisk
OncoPep Inc
OSE Immunotherapeutics
Oxford BioTherapeutics Ltd
Pieris Pharmaceuticals
Pique Therapeutics
Recepta Biopharma
Regen Biopharma Inc
Regeneron Pharmaceuticals

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook